“These promising nonclinical data, generated by the FDA, are another indicator that SAB -185 may have broad potential as an effective therapy for the treatment of COVID-19 infections across both ...

Preclinical data has also indicated that SAB-185 is significantly more potent than human-derived convalescent immunoglobulin G (IgG).

Preclinical data has also indicated that SAB-185 is significantly more potent than human-derived convalescent immunoglobulin G (IgG).

Data Results: 66% of participants treated with SAB-185 reached full symptom resolution for at least four consecutive days by Day 28, while only 50% of participants on REGEN-COV met this endpoint ...

SAB Biotherapeutics SABS reported data from the phase II study evaluating SAB-185, its intravenously administered polyclonal antibody treatment of high-risk non-hospitalized patients with mild-to ...

SAB BIO's SAB-142 Phase 1 trial data supports its safety and pharmacodynamic activity, paving the way for a Phase 2b trial in T1D in 2025.

“SAB’s data on SAB-176 and SAB-185 validated that our platform delivers on its promise and can create fully-human antibodies that offer much broader efficacy in highly mutating pathogens ...

“These promising in vitro data show that SAB-185 can neutralize SARS-CoV-2 spike-containing viruses, including those with mutations present in some variants of concern and accordingly represents ...